CA2493282C - Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques - Google Patents

Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques Download PDF

Info

Publication number
CA2493282C
CA2493282C CA2493282A CA2493282A CA2493282C CA 2493282 C CA2493282 C CA 2493282C CA 2493282 A CA2493282 A CA 2493282A CA 2493282 A CA2493282 A CA 2493282A CA 2493282 C CA2493282 C CA 2493282C
Authority
CA
Canada
Prior art keywords
urease
cancer
cells
tumor
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2493282A
Other languages
English (en)
Other versions
CA2493282A1 (fr
Inventor
Donald Segal
Jerry Mcelroy
Heman Chao
Wah Y. Wong
John Docherty
Jodi Dickstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biopharma Corp
Original Assignee
Helix Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp filed Critical Helix Biopharma Corp
Priority to CA2493282A priority Critical patent/CA2493282C/fr
Publication of CA2493282A1 publication Critical patent/CA2493282A1/fr
Application granted granted Critical
Publication of CA2493282C publication Critical patent/CA2493282C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Lamélioration des procédés de traitement du cancer à laide de composés anti-cancéreux faiblement basiques est décrite. Selon un aspect, linvention concerne une amélioration dun procédé de traitement de cellules cancéreuses dont lenvironnement extracellulaire contient 1 à 8 mM durée en exposant les cellules à un composé anti-cancéreux faiblement basique pouvant être utilisé efficacement dans linhibition de la croissance des cellules. Lamélioration comprend (a) lexposition des cellules à une composition enzymatique duréase et, (b) par létape (a), la réduction de la quantité du composé anti-cancéreux requis pour produire une ampleur donnée de linhibition dans la croissance des cellules lorsque les cellules sont exposées à lagent anti-cancéreux. Les procédés de potentialisation de lactivité thérapeutique spécifique dun composé anti-cancéreux faiblement basique dans le traitement dun cancer mammalien qui est réactif au composé sont fournis, tout comme les compositions pharmaceutiques destinées à être utilisées dans une administration intraveineuse à un sujet.
CA2493282A 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques Active CA2493282C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2493282A CA2493282C (fr) 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2493282A CA2493282C (fr) 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques

Publications (2)

Publication Number Publication Date
CA2493282A1 CA2493282A1 (fr) 2006-07-31
CA2493282C true CA2493282C (fr) 2020-05-12

Family

ID=36764070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2493282A Active CA2493282C (fr) 2005-01-31 2005-01-31 Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l'aide de l'urease et de composes anti-cancereux faiblement basiques

Country Status (1)

Country Link
CA (1) CA2493282C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022891A (zh) 2016-09-24 2019-07-16 赫利克斯生物药品公司 恢复肿瘤酸化t细胞的功能

Also Published As

Publication number Publication date
CA2493282A1 (fr) 2006-07-31

Similar Documents

Publication Publication Date Title
US20210177929A1 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
US20100189643A1 (en) Drug delivery with stimulus responsive biopolymers
EP3261678B1 (fr) Conjugués anticorps-uréase pour des fins thérapeutiques
IL166249A (en) Use of urease enzyme for the preparation of medicaments for inhibiting cancer cell growth
JP2022541650A (ja) ペプチド核酸系の作用物質を用いて癌を治療するための方法および組成物
Xia et al. Self-assembled nanomicelles of affibody-drug conjugate with excellent therapeutic property to cure ovary and breast cancers
US6638508B2 (en) Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
US7264800B2 (en) Method and composition for inhibiting cancer cell growth
CA2493282C (fr) Methode et composition destinees a inhiber la proliferation de cellules cancereuses a l&#39;aide de l&#39;urease et de composes anti-cancereux faiblement basiques
KR102387320B1 (ko) 약물 반응성 예측을 위한 대장암 진단 또는 검출용 조성물, 대장암 예방 또는 치료용 조성물
US20240058371A1 (en) Molecule for inducing spontaneous calcification of tumor cells and use thereof
CA3017958A1 (fr) Ciblage de cellules tumorales avec des agents chimiotherapeutiques conjugues a des anticorps anti-matriptase par des parties de liaison clivables in vivo
PL227543B1 (pl) Sposób wytwarzania koniugatu fibrynogenu glikowanego glukozą z metotreksatem

Legal Events

Date Code Title Description
EEER Examination request